Scientific Resources Related to ADME, DMPK in Drug Development

Access ADME™ Resource Categories

For convenience, we have tagged our scientific informational content with a specific category so you can see everything we have relevant to your interest area within drug metabolism and DDI. Resources can also be viewed by type, so you can access all recent content in a specific type, e.g., posters or webinars, if you so choose. Within each category, you can find all relevant resource formats to read or watch.

Request a Webinar Topic

ADME 101™

ADME 101™ is a series of short, digestible videos of presentations given by our in-house experts, each relevant to a different topic within ADME, DDI, and DMPK components of drug development.

Biologics & Oligonucleotides

Our in-house expert teams have presented research and developed assays to explore specific intersections of biologics and small molecules in the context of DDI prediction.

Disease-Specific Resources

Find resources describing research investigating various liver diseases including NASH, NAFLD, steatosis, diabetes, and more. Our resources provide you with insight into effective research models and methods to explore function, impairment, and therapeutic response for various liver disease states.

Drug Drug Interactions (DDI)

Drug-drug interactions (DDIs) may occur when taking two (or more) drugs together results in altered efficacy or behavior of one or both drugs, potentially causing adverse effects. Preclinical studies to evaluate perpetrator and victim potential of their compound comprise a critical component of safety testing.

Drug Metabolism

Drug metabolism research seeks to identify metabolic pathways and likely metabolites formed by a compound, as well as identify drug-metabolizing enzymes involved in its biotransformation.

Drug Transporters

Drug transporter-related research explores interactions between xenobiotics and uptake (SLC) or efflux (ABC) transporters, which could precipitate drug-drug interactions.

Enzyme Induction

Enzyme Induction describes a xenobiotic compound’s likelihood to increase the clearance of a concomitant (victim) drug by up-regulating (inducing) enzymes that metabolize it.

Enzyme Inhibition

Enzyme Inhibition describes a xenobiotic compound’s inhibitory effect on drug-metabolizing enzymes to evaluate potential for drug-drug interactions that may increase toxicity or reduce therapeutic effect of concomitant medications.

In Vivo & Radiolabeling

In vivo and radiolabeled compound details are necessary for distribution data, dosing calculations for first in-human studies, bridging in vitro PK, toxicology data, and more.

Non-CYP Enzymes

While Cytochrome P450 (CYP) enzymes are well-known and profiled for their role in metabolism of many small molecule drugs, other enzymes can play critical roles in a drug compound’s metabolism and overall disposition in a similar way.

Regulatory Guidance

As regulatory authorities, such as the FDA, EMA, and PMDA, come out with updated guidance and calls for comment, our in-house experts frequently present and compose content to tell you what relevant updates mean for you as a drug developer.

Test Systems & Methods

As test systems become introduced and subsequently vetted by CROs and the scientific community for value and utility in quality, predictive assays, we compile relevant studies and research relating to those which are commonly used or suggested by regulatory authorities for in-house testing.

Helpful Links

Find information on our partners and distributors, scientific community membership, or how to follow us on social media and receive newsletters.